WO2026046233 - COUMARIN COMPOUND AND USE THEREOF
National phase entry is expected:
Publication Number
WO/2026/046233
Publication Date
05.03.2026
International Application No.
PCT/CN2025/117239
International Filing Date
27.08.2025
Title **
[English]
COUMARIN COMPOUND AND USE THEREOF
[French]
COMPOSÉ DE COUMARINE ET SON UTILISATION
[Chinese]
香豆素类化合物及其应用
Applicants **
SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.
Inventors
MAI, Wansun
LIU, Xiaowu
DENG, Zhixiong
WANG, Tao
ZHOU, Yike
SONG, Jianing
ZHU, Wei
LI, Zhengtao
HU, Mengnan
Priority Data
202411192859.7
28.08.2024
CN
202411970980.8
30.12.2024
CN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2042 | |
| EPO | Filing, Examination, Granting | 15408 | |
| Japan | Filing, Examination, Granting | 2389 | |
| South Korea | Filing, Examination, Granting | 2594 | |
| USA | Filing, Examination, Granting | 5140 |
Total:
27,573
Contact Us
Abstract[English]
The content of the present disclosure relates to an MEK-targeting compound. Specifically provided is a compound of formula (IA) or formula (IB) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof. The compound has the substituents and structural features as described in the present application. Further described in the present application are a pharmaceutical composition containing the compound of formula (IA) or formula (IB) or the stereoisomer thereof or the pharmaceutically acceptable salt thereof, and the pharmaceutical use of the compound or the stereoisomer thereof or the pharmaceutically acceptable salt thereof.[French]
La présente divulgation concerne un composé ciblant MEK. L'invention concerne en particulier un composé de formule (IA) ou de formule (IB) ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci. Le composé présente les substituants et les caractéristiques structurales tels que décrits dans la présente demande. La présente demande concerne en outre une composition pharmaceutique contenant le composé de formule (IA) ou formule (IB) ou un stéréoisomère ou un sel pharmaceutiquement acceptable de celui-ci , et l'utilisation pharmaceutique du composé ou du stéréoisomère ou du sel pharmaceutiquement acceptable de celui-ci.[Chinese]
本公开内容涉及靶向MEK的化合物，具体提供了式(IA)或式(IB)的化合物或其立体异构体或其药学上可接受的盐，所述化合物具有本申请所述取代基和结构特征。本申请还描述了包含式(IA)或式(IB)化合物或其立体异构体或其药学上可接受的盐的药物组合物，以及所述化合物或其立体异构体或其药学上可接受的盐在医药上的应用。